Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery

Xiaofei Liang; Bizhi Shi; Kai Wang; Mingliang Fan; Dejin Jiao; Junping Ao; Na Song; Chun Wang; Jianren Gu; Zonghai Li

doi:10.1016/j.biomaterials.2015.12.015

Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery

Xiaofei Liang, Bizhi Shi, Kai Wang, Mingliang Fan, Dejin Jiao, Junping Ao, Na Song, Chun Wang, Jianren Gu, Zonghai Li

Biomedical Engineering

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

Development of rational vectors for efficient drug and gene delivery is crucial for cancer treatment. In this study, epidermal growth factor receptor (EGFR)-binding peptide amphiphile (PA) were used as the primary bilayer skeleton material to construct ultra-stable self-assembling peptide nanovesicle (SPV). The resulted EGFR-targeted SPV (ESPV) could efficiently encapsulate therapeutic cargos (drugs or small interfering RNAs [siRNAs]) or labelled fluorescent cargo (quantum dots [QDs]) and exhibited excellent affinity for EGFR-positive cancer cells. Moreover, ESPV could deliver more drug or plasmid DNA to tumour sites and promote gene expression (a three-fold ratio of ESPVs vs cationic liposomes). Notably, the individual delivery or co-delivery of doxorubicin (DOX) and the acetylcholinesterase (AChE) gene via the ESPVs resulted in excellent drug/gene delivery both in vitro and in vivo and exerted a significant growth-suppressing effect on a liver cancer xenograft. This nanoscale, targeted cargo-packaging technology may provide a new strategy for the design of highly targeted cancer therapy vectors.

Original language	English (US)
Pages (from-to)	194-207
Number of pages	14
Journal	Biomaterials
Volume	82
DOIs	https://doi.org/10.1016/j.biomaterials.2015.12.015
State	Published - Mar 1 2016

Bibliographical note

Funding Information:
This work was supported by The National Natural Science Foundation of China (No. 81572973 ), the small and medium-sized enterprise innovation fund of Shanghai (No. 1302H159400), the Biological Medicine Industry-University-research Project of Shanghai (Grant no. 12DZ1941702 ), the Supporting Program of the “Twelfth Five-year Plan” for Science and Technology Research of China (No. 2012ZX09103-301-006 ), National Basic Research Program (No. 2010CB529902 ), the Biological Medicine Industry-University-research Project of Shanghai (No. 12DZ1941702 ) and The National Natural Science Foundation of China (No. 81302708 ). We thank the Instrumental Analysis Center of Shanghai Jiao Tong University for materials testing.

Publisher Copyright:
© 2015 Elsevier Ltd.

Keywords

Cancer therapy
Gene and drug delivery
Liposome
Peptide
Tumour-targeted nanocarrier

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.biomaterials.2015.12.015

OpenUrl availability

Full text

Cite this

@article{7bbbd70fd939458ba914da40361b7b90,

title = "Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery",

abstract = "Development of rational vectors for efficient drug and gene delivery is crucial for cancer treatment. In this study, epidermal growth factor receptor (EGFR)-binding peptide amphiphile (PA) were used as the primary bilayer skeleton material to construct ultra-stable self-assembling peptide nanovesicle (SPV). The resulted EGFR-targeted SPV (ESPV) could efficiently encapsulate therapeutic cargos (drugs or small interfering RNAs [siRNAs]) or labelled fluorescent cargo (quantum dots [QDs]) and exhibited excellent affinity for EGFR-positive cancer cells. Moreover, ESPV could deliver more drug or plasmid DNA to tumour sites and promote gene expression (a three-fold ratio of ESPVs vs cationic liposomes). Notably, the individual delivery or co-delivery of doxorubicin (DOX) and the acetylcholinesterase (AChE) gene via the ESPVs resulted in excellent drug/gene delivery both in vitro and in vivo and exerted a significant growth-suppressing effect on a liver cancer xenograft. This nanoscale, targeted cargo-packaging technology may provide a new strategy for the design of highly targeted cancer therapy vectors.",

keywords = "Cancer therapy, Gene and drug delivery, Liposome, Peptide, Tumour-targeted nanocarrier",

author = "Xiaofei Liang and Bizhi Shi and Kai Wang and Mingliang Fan and Dejin Jiao and Junping Ao and Na Song and Chun Wang and Jianren Gu and Zonghai Li",

note = "Funding Information: This work was supported by The National Natural Science Foundation of China (No. 81572973 ), the small and medium-sized enterprise innovation fund of Shanghai (No. 1302H159400), the Biological Medicine Industry-University-research Project of Shanghai (Grant no. 12DZ1941702 ), the Supporting Program of the “Twelfth Five-year Plan” for Science and Technology Research of China (No. 2012ZX09103-301-006 ), National Basic Research Program (No. 2010CB529902 ), the Biological Medicine Industry-University-research Project of Shanghai (No. 12DZ1941702 ) and The National Natural Science Foundation of China (No. 81302708 ). We thank the Instrumental Analysis Center of Shanghai Jiao Tong University for materials testing. Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd.",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.biomaterials.2015.12.015",

language = "English (US)",

volume = "82",

pages = "194--207",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery

AU - Liang, Xiaofei

AU - Shi, Bizhi

AU - Wang, Kai

AU - Fan, Mingliang

AU - Jiao, Dejin

AU - Ao, Junping

AU - Song, Na

AU - Wang, Chun

AU - Gu, Jianren

AU - Li, Zonghai

N1 - Funding Information: This work was supported by The National Natural Science Foundation of China (No. 81572973 ), the small and medium-sized enterprise innovation fund of Shanghai (No. 1302H159400), the Biological Medicine Industry-University-research Project of Shanghai (Grant no. 12DZ1941702 ), the Supporting Program of the “Twelfth Five-year Plan” for Science and Technology Research of China (No. 2012ZX09103-301-006 ), National Basic Research Program (No. 2010CB529902 ), the Biological Medicine Industry-University-research Project of Shanghai (No. 12DZ1941702 ) and The National Natural Science Foundation of China (No. 81302708 ). We thank the Instrumental Analysis Center of Shanghai Jiao Tong University for materials testing. Publisher Copyright: © 2015 Elsevier Ltd.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Development of rational vectors for efficient drug and gene delivery is crucial for cancer treatment. In this study, epidermal growth factor receptor (EGFR)-binding peptide amphiphile (PA) were used as the primary bilayer skeleton material to construct ultra-stable self-assembling peptide nanovesicle (SPV). The resulted EGFR-targeted SPV (ESPV) could efficiently encapsulate therapeutic cargos (drugs or small interfering RNAs [siRNAs]) or labelled fluorescent cargo (quantum dots [QDs]) and exhibited excellent affinity for EGFR-positive cancer cells. Moreover, ESPV could deliver more drug or plasmid DNA to tumour sites and promote gene expression (a three-fold ratio of ESPVs vs cationic liposomes). Notably, the individual delivery or co-delivery of doxorubicin (DOX) and the acetylcholinesterase (AChE) gene via the ESPVs resulted in excellent drug/gene delivery both in vitro and in vivo and exerted a significant growth-suppressing effect on a liver cancer xenograft. This nanoscale, targeted cargo-packaging technology may provide a new strategy for the design of highly targeted cancer therapy vectors.

AB - Development of rational vectors for efficient drug and gene delivery is crucial for cancer treatment. In this study, epidermal growth factor receptor (EGFR)-binding peptide amphiphile (PA) were used as the primary bilayer skeleton material to construct ultra-stable self-assembling peptide nanovesicle (SPV). The resulted EGFR-targeted SPV (ESPV) could efficiently encapsulate therapeutic cargos (drugs or small interfering RNAs [siRNAs]) or labelled fluorescent cargo (quantum dots [QDs]) and exhibited excellent affinity for EGFR-positive cancer cells. Moreover, ESPV could deliver more drug or plasmid DNA to tumour sites and promote gene expression (a three-fold ratio of ESPVs vs cationic liposomes). Notably, the individual delivery or co-delivery of doxorubicin (DOX) and the acetylcholinesterase (AChE) gene via the ESPVs resulted in excellent drug/gene delivery both in vitro and in vivo and exerted a significant growth-suppressing effect on a liver cancer xenograft. This nanoscale, targeted cargo-packaging technology may provide a new strategy for the design of highly targeted cancer therapy vectors.

KW - Cancer therapy

KW - Gene and drug delivery

KW - Liposome

KW - Peptide

KW - Tumour-targeted nanocarrier

UR - http://www.scopus.com/inward/record.url?scp=84957605448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957605448&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2015.12.015

DO - 10.1016/j.biomaterials.2015.12.015

M3 - Article

C2 - 26763734

AN - SCOPUS:84957605448

SN - 0142-9612

VL - 82

SP - 194

EP - 207

JO - Biomaterials

JF - Biomaterials

ER -

Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this